Antiemetic research: a look to the future

Area of Science:

• Pharmacology and Neuroscience
• Oncology
• Medical Imaging

Background:

• The understanding of receptors governing the emetic reflex has undergone significant transformation in the last decade.
• Current research focuses on novel therapeutic agents, including combined serotonin 5-HT3 antagonists/5-HT4 agonists, dopamine D2/D3 antagonists, and neurokinin1 antagonists.

Purpose of the Study:

• To review the evolving landscape of emetic reflex receptor classification and novel antiemetic agents.
• To highlight the emerging role of Positron Emission Tomography (PET) in cancer research and its potential application in studying emesis.
• To identify persistent challenges in antiemetic therapy, particularly refractory and delayed emesis in cancer patients.

Main Methods:

• Review of recent advancements in receptor classification for the emetic reflex.
• Discussion of investigational antiemetic agents targeting specific receptor pathways.
• Exploration of Positron Emission Tomography (PET) applications in oncology and emesis pathophysiology.

Main Results:

• Significant shifts in receptor classification for the emetic reflex have occurred.
• Novel therapeutic agents targeting 5-HT3, 5-HT4, dopamine D2/D3, and neurokinin1 receptors are under investigation.
• Positron Emission Tomography (PET) is a valuable tool for cancer detection, staging, treatment response evaluation, and potentially for emesis research.

Conclusions:

• Despite optimized antiemetic treatments, challenges such as delayed, cyclical, and refractory emesis persist, necessitating further clinical investigation.
• Chronic nausea and vomiting in advanced cancer patients remain a significant clinical issue requiring dedicated research.
• The integration of advanced imaging techniques like PET may offer new insights into the mechanisms of emesis and guide therapeutic strategies.